Jerusalem Bio-Park 5th floor
Hadassah Medical Center Campus, POB 12057
About NovellusDxFounded in 2011, NovellusDX has brought together a team of skilled individuals from several fields, including synthetic biology, functional genomics, bioinformatics, engineering, algorithm development, clinical laboratory and healthcare commercialization.
CEO: Haim Gil-Ad
CCO: Michael Vidne
Please click here for NovellusDx job opportunities.
9 articles with NovellusDx
Investors include: Pontifax, OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Asset Management, Novartis Venture Fund (NVF), SR One, and existing investors. Proceeds will fund the clinical development of PLX-8394 for patients with BRAF fusions and glioma patients with BRAF mutations. JERUSALEM--( BUSINESS WIRE )-- Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology announced today
Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical Stage BRAF Inhibitor
Novellus, a precision-oncology drug development company, announced today that it has entered into an exclusive worldwide license agreement with Plexxikon, a member of the Daiichi Sankyo Group, for PLX8394, its clinical-stage oncology drug candidate which targets the BRAF protein. PLX8394 is currently completing a Ph
Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDx., a leader in functional genomics, for the firm's agreement to merge with a newly formed Israeli subsidiary of Cancer Genetics, Inc.. (NASDAQ: CGIX).
NovellusDx, Ltd. and Primetech Co., Ltd. announce that Primetech will provide NovellusDx' functional genomics assay "FACT – Functional Annotation for Cancer Treatment" as an exclusive dealer in Japan for the pre-clinical market with sales, marketing and research support / technical support in Japan.
Helsinn Investment Fund, Bio Capital Impact Fund and Windham Venture Partners Join a Leading Investor Syndicate to Support the Commercialization Efforts Of NovellusDx
NovellusDx announced it has completed an equity financing of $6 million.
NovellusDx to perform retrospective analysis of the MOST clinical trial to test the predictive ability of its functional assay in cancer patients.
Centre Léon-Bérard and the biotechnology company NovellusDx are collaborating on a retrospective analysis of two study arms of the MOST trial.
New Partnership Between Christiana Care’s Gene Editing Institute And NovellusDx Speeds Progress Toward Personalized Cancer Medicine
NovellusDx Announced Today The Completion Of The First Phase Of An In-Vitro Study Of BioMed Valley Discoveries' BVD523
NovellusDx Registers Another Patent On Their FACT System, Publishes A New Study With Guardant Health And MD Anderson Cancer Center In Cancer Discovery; Was Selected To Present At Biomed, BIO 2017 And ASCO